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Androstenediol (androst-5-ene-3β,17β-diol; 5-AED), a natural adrenal steroid, has been shown to suppress experimental
autoimmune encephalomyelitis (EAE) in female SJL/J mice. We here report that 5-AED limits inﬂammation and proinﬂammatory
cytokinesincludingTNFαinmurinemodelsofcarrageenan-inducedpleurisyandlippopolysaccaride-(LPS)inducedsepticshock.
5-AED binds to and transactivates sex steroid receptors with the same general rank order of potency (ERβ>ERα   AR). 5-AED
providesbeneﬁtinEAEinadose-dependentfashion,evenwhentreatmentisdelayeduntilonsetofdisease.Theminimallyeﬀective
dose may be as low as 4mg/kg in mice. However, beneﬁt was not observed when 5-AED was given in soluble formulation, leading
to a short half-life and rapid clearance. These observations suggest that treatment with 5-AED limits the production of pro-
inﬂammatory cytokines in these animal models and, ultimately, when formulated and administered properly, may be beneﬁcial
for patients with multiple sclerosis and other Th1-driven autoimmune diseases.
1.Introduction
Nonglucocorticoid steroids are subjects of intense scientiﬁc
investigation as perturbations are associated with various
diseases including the pathogenesis of autoimmunity [1].
The“gendergap”[2]withrespecttoincidenceandseverityof
autoimmune disease has been the focus of eﬀorts to uncover
new therapies. For example, estrogens [3] and androgens [4,
5] are protective in several autoimmune disease models, inc-
luding experimental autoimmune encephalomyelitis (EAE),
an animal model for multiple sclerosis (MS).
Recent work has dissociated the anti-inﬂammatory eﬀect
from the neuroprotective eﬀect of estrogen treatment in
EAE and has shown that its neuroprotective eﬀects do not
necessarily depend on anti-inﬂammatory properties [6].
Speciﬁcally, an estrogen receptor (ER)α agonist reduced
central nervous system inﬂammation, whereas an ERβ ago-
nist treatment did not, but instead, was neuroprotective.
Preliminary clinical results were encouraging. In a pilot trial,
oralestrioltreatmentofrelapsingremittingmultiplesclerosis
patients caused signiﬁcant decreases in enhancing lesions
on brain magnetic resonance imaging [7]. However, sex
steroid therapy involves serious risks. For example, estrogen
treatment involves increased risk for breast cancer in women
[8]. Because such estrogen-related toxicities are mediated
almost exclusively through ERα,E R β ligand treatment has
been suggested as a potentially safer neuroprotective strategy
in multiple sclerosis and other neurodegenerative diseases.
Alternatively, we have suggested that risks associated with
ERα could be minimized by the use of safe synthetic der-
ivatives [9] or low-dose estrogen that produces synergistic
eﬀects when used in combination with another immuno-
regulatorytherapy [10].We havealsoproposed useofrelated
steroids [11] such as androstenediol (androst-5-ene-3β,17β-
diol; 5-AED) that may result in optimal, simultaneous
engagement of multiple sex steroid receptors.2 Autoimmune Diseases
Treatment with 5-AED (40mg/kg) provided signiﬁcant
beneﬁt when given at disease onset in the SJL/J female mouse
model of EAE [11]. 5-AED was also anti-inﬂammatory as we
observed an increased survival in a murine model of LPS-
induced shock and reduced neutrophil burden in a murine
model of carrageenan-induced pleurisy. Finally, a dramatic
increase in the Th2 associated response was observed in the
popliteal lymph node assay (i.e., B cell/T cell ratio, antigen
speciﬁc IgM and IgG1, as well as IL-4 production). Here
those observations are conﬁrmed and extended. We now
report that 5-AED reduced both inﬂammatory cells and
cytokines (TNFα and IL-6) in murine pleurisy and reduced
serum levels of TNFα as well as improved survival in LPS-
induced shock. 5-AED provided dose-dependent beneﬁt in
the SJL/J female mouse model of EAE, with a minimally
eﬀective dose of between 40 and 4mg/kg. In contrast to an
injection of a suspension formulation, injection of 5-AED
in a solution formulation was not eﬀective. 5-AED binds
to and transactivates sex steroid receptors with the same
general rank order of potency (ERβ>ERα   AR). Taken
together with our clinical observations, these studies suggest
that treatment with 5-AED may provide safe and eﬃcacious
beneﬁts to patients with MS.
2. Methods
2.1. Drugs. Test compound androst-5-ene-3β,17β-diol (5-
AED) and vehicles (HERF202 or HERF405) were provided
by Harbor Biosciences (San Diego, CA). HERF202 was com-
prised of 30% β-cyclodextrin sulfobutyl ether sodium salt
(w/v) in water and formed a solution of the test compound.
HERF405 comprised of 0.1% carboxymethylcellulose, 2%
polysorbate80and0.1%metabisulﬁteinphosphate-buﬀered
salinepH7.4andformedasuspensionofthetestcompound.
2.2. Nuclear Receptor Binding Assays. Assessment of binding
activity for various nuclear receptors was performed by
homogeneous competition assays using the PolarScreen
ﬂuorescencepolarizationsystem(InVitrogen,Carlsbad,CA).
Brieﬂy, serial dilutions of 5-AED or a reference competitor
were incubated on 384-well plates for 2 hours at room tem-
perature in the presence of an appropriate ﬂuorescent ligand
(Fluormone) and a nuclear receptor of recombinant origin
(AR, no. P3018; GR, no. P2816; ERα, no. P2614; ERβ,n o .
P2615; PR, no. P2895) in a total volume of 30μL, following
the manufacturer’s instructions. Fluorescence polarization
(FP) in each well was determined with a GENios Pro reader
(Tecan,SanJose,CA),andbasedontheextentofFPsuppres-
siondetected,IC50 competitionvalueswerederivedusingthe
GraphPad Prism software (GraphPad, San Diego, CA). Most
nuclear receptors employed in these assays are full-length
recombinant proteins of human origin, with the exception
of AR (His/GST-tagged rat AR ligand binding domain) and
PR (GST-tagged human PR ligand binding domain).
2.3. Nuclear Receptor Transactivation Assays. Transactivation
of sex steroid or corticosteroid receptors was assessed in
the stable transfectant human cancer cell lines MDA-kb2
(American Type Culture Collection (ATCC) no. CRL-2713)
and T47D-kBluc (ATCC no. 2865), which express AR/GR
andERα/β,r especti v ely[12,13].Brieﬂy,cellswereplatedat2
×104 cells/wellin96-wellclearbottomwhiteassaymicrotiter
plates (Corning, Lowell, MA) in 100μL phenol red-free
RPMI-1640 medium supplemented with 4mM L-glutamine
and 10% charcoal-stripped fetal bovine serum (CHAR-
DEX FBS; InVitrogen). Cells were incubated overnight
with the various compounds and luciferase activity was
then determined in cell lysates. Transactivation activity of
the human mineralocorticoid receptor (MR) and peroxi-
some proliferator-activated receptors (PPAR-γ and PPAR-
δ) used the ﬂuorimetric Gene Blazer β-lactamase assay sys-
tem (InVitrogen) following the manufacturer’s instructions.
Assayswereconductedon384-wellplatesusingaﬂuorogenic
substrate (CCF4-AM, InVitrogen). Reference compounds
(Tocris, Ellisville, MO) used for each receptor were Rosigli-
tazone and GW1929 for PPAR-γ (EC50 = 1.3nM), L165,041
for PPAR-δ (EC50 = 1.1 nM), and aldosterone for MR (EC50
= 0.02 nM).
2.4. Carrageenan-Induced Pleurisy
2.4.1. Animals. 6-to-8-week-old CD1 male mice (Harlan,
San Diego) were used for the carrageenan- (CAR-) induced
pleurisy studies. The animals were housed in a controlled
environment and provided with standard rodent chow and
water. Animals were housed in the Animal Resource Facility
at the La Jolla Institute of Molecular Medicine (San Diego,
CA) in accordance with institutional guidelines.
2.4.2. Experimental Groups. Mice (4 per group) were treated
by subcutaneous (s.c.) injection either with 100μL of 5-AED
suspension (40mg/kg) or with vehicle alone 24 hours and 1
hour before CAR challenge. Groups of mice were sacriﬁced
at 4 -, 5 -, and 6-hour time points after CAR challenge.
2.4.3. Pleurisy. Mice were anaesthetized with isoﬂurane and
the skin was incised at the level of the left sixth intercostal
space. The underlying muscle was dissected and saline
(0.1mL) or saline containing 2% λ-CAR (0.1mL; Sigma
Chimica, Milan, Italy) was injected into the pleural cavity.
The skin incision was closed with a suture and the animals
were allowed to recover. At 4–6 hours after the injection
of CAR, the animals were euthanized by inhalation of
CO2. The chest was carefully opened and the pleural cavity
rinsed with 1mL of saline solution containing heparin
(5U/mL) and indomethacin (10μg/mL). Any exudate (in
these studies, less than 200μL) and washing solution were
removed by aspiration. Granuclocytes were suspended in
PBS, and enumerated by FACscan with standard software
(BD Biosciences, Franklin Lakes, NJ). Levels of TNFα and
IL-6 in plural rinse were determined by ELISA (Biosource
International, Camarillo, CA).
2.4.4. Statistical Analysis. All values in the ﬁgures are
expressed as mean ± standard deviation. Results were
analyzedby two-sided Student’st-test.A P valueof<. 05 was
considered signiﬁcant.Autoimmune Diseases 3
2.5. LPS-Induced Shock
2.5.1. Mice. Six-week-old CD1 mice (Charles River, Calco,
Italy) were kept under standard laboratory (nonspeciﬁc
pathogen free) conditions at the University of Catania,
School of Medicine, and were housed in a controlled
environment and provided with standard rodent chow and
water. Animal care and use was in compliance with all
applicable regulations on protection of animals used for
experimental and other scientiﬁc purposes.
2.5.2. Induction of Septic Shock and Experimental Treatment.
To induce lethal endotoxemia, the mice were injected i.p.
with 1mg LPS (Sigma Chimica, Milan, Italy, code L6011,
Lot K4096). Groups of female mice (n = 10) were treated
(s.c) with either 100μL of 5-AED suspension (40mg/kg) or
with vehicle 24 hours before or 1, 2, 4, 8, or 24 hours after
the LPS challenge. In some studies (performed by Harbor
Biosciences) male mice (n = 4p e rg r o u p )w e r eu s e da n d
serum was taken 2 hours after LPS (0.5mg) challenge, to
measure levels of TNFα by ELISA.
2.5.3. Statistical Analysis. Statistical analysis was performed
by chi-square for cumulative lethality assessed at 72 hours
after LPS injection or by Student’s t-test. All P-values of less
than .05 were considered signiﬁcant. For statistical analysis
each group is compared to that of vehicle-treated control.
2.6. Experimental Autoimmune Encephalomyelitis (EAE)
2.6.1. EAE Studies of 5-AED Suspension. 5-AED suspension
was tested by F.N. at the University of Catania, Catania, Italy,
as in our previous studies [14].
Mice. Female SJL/J mice (6 to 8 weeks of age; Charles River
Italia, Udine, Italy) were maintained in a pathogen-free
vivarium at the University of Catania, School of Medicine
(Catania, Italy) receiving ad libitum sterilized food and
water, and were adapted to the ambient environment for at
least 7 days before the start of the study. Animal care and
use was in compliance with all applicable regulations for
the protection of animals used for experimental and other
scientiﬁc purposes.
Induction of EAE and Experimental Treatment. Relapsing
and remitting EAE was induced via s.c. injection of
(PLP)(139–151) as in our previous studies [14]. Disease
symptoms were monitored daily and scored in a blinded
manner using the following scale: 0: no illness, 1: ﬂaccid tail,
2: moderate paraparesis, 3: severe paraparesis, 4: moribund
state, 5: death. Mice were randomized to each experimental
group before immunization to induce EAE. Treatment
with 100μL of either 5-AED (0.4, 4.0 or 40mg/kg) or
vehicle was initiated on Day 8 post immunization, when
disease onset was ﬁrst observed, and continued 6 times per
week until Day 30 post-immunization. Statistical analysis
of cumulative clinical scores was performed by ANOVA
analysis for unpaired data. A P-value <.05 was considered
Table 1: Competition binding IC50 values of dihydrotestosterone
(DHT), estradiol (E2), and androstenediol (5-AED) for AR, ERα,
and ERβ.
Ligand Receptor∗
AR
(a) ERα
(b) ERβ
(c)
DHT 15nM ± 4.2 (4) ND∗∗ ND
E2 ND 8nM ± 5.4 (3) 7nM ± 1.6 (3)
5-AED 210nM ± 44 (4) 49nM ± 13 (4) 10 nM ± 3.4 (4)
∗R e s u l t sa r ee x p r e s s e da sI C 50 values in nM units, representing the
statistical mean ± SEM. The numbers in parenthesis represent the number
of independent experiments performed (n value). See text for details of
procedures.
(a)AR: Human androgen receptor.
(b)ERα:H u m a ne s t r o g e nr e c e p t o rα.
(c)ERβ:H u m a ne s t r o g e nr e c e p t o rβ.
∗∗ND: Not determined.
to be statistically signiﬁcant. For statistical analysis, the mice
that succumbed to EAE were assigned 5 only for the day of
death and then were deleted from the experimental group.
2.6.2. EAE Studies of 5-AED Solution. Studies of soluble 5-
AED solution were performed by H.O. at the Oregon Health
Science University, Portland OR, as in our previous studies
[11].
Mice. Pathogen free female SJL/J mice (6–8 weeks old) were
used for these studies. The mice were housed in the Animal
Resource Facility at the Portland Veterans Aﬀairs Medical
Center in accordance with institutional guidelines.
Induction of EAE and Experimental Treatment. Relapsing
and remitting EAE was induced via s.c. injection of
(PLP)(139–151) as in our previous studies [11]. Mice were
given s.c injections (100μL) of either 5-AED solution
(40mg/kg) or vehicle every day after onset of disease (11
days post immunization to EAE induction). The mice were
assessed daily for clinical signs of EAE according to the
following scale: 0: no signs; 1: limp tail or mild hind limb
weakness; 2: moderate hind limb weakness or mild ataxia; 3:
moderately severe hind limb weakness; 4: severe hind limb
weakness or mild forearm weakness or moderate ataxia; 5:
paraplegia with no more than moderate forelimb weakness;
6: paraplegia with severe forelimb weakness or severe ataxia
or moribund condition.
3. Results
3.1. Diﬀerential Engagement of Sex Steroid Receptors by 5-
AED. 5-AED does not transactivate human mineralocor-
ticoid, glucocorticoid, or peroxisome proliferator-activated
receptors (PPAR-γ and PPAR-δ) (data not shown).
5-AED binds competitively to the sex steroid receptors
in a speciﬁc rank order (ERβ>ERα   AR). It binds
with relatively high aﬃnity to both ERα and ERβ,b u to n l y
modestly to AR, and it is nearly equivalent to 17β-estradiol
ERβ binding (10nM versus 7nM; see Table 1). Three
experimental systems were used to obtain information4 Autoimmune Diseases
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Figure 1: Eﬀect of 5-AED on numbers of PMN and cytokine levels in murine model of CAR-induced pleurisy. Male CD-1 mice (n = 4
per group) were anaesthetized with isoﬂurane, and saline (0.1mL) or saline containing 2%λ-CAR (0.1mL) was injected into the pleural
cavity. Mice were treated (s.c.) with 5-AED in vehicle (squares) or with vehicle alone (triangles) 24 hours and 1 hour before CAR challenge.
At 4–6 hours after the injection of CAR, the pleural cavity was rinsed with 1mL of saline solution. Any exudate (less than 0.2mL in these
studies) and washing solution was removed by aspiration. The leukocytes were suspended in phosphate-buﬀer saline (PBS) and evaluated
by FACscan analysis of live cells in suspension. Cytokine levels were measured by ELISA. All values in the ﬁgures expressed as mean ± one
standard deviation. These studies were repeated twice with similar results. ∗Indicates signiﬁcant (P<. 05) diﬀerence when compared to
control values.
regarding the capacity of 5-AED to transactivate these
sex steroid receptors (Table 2). As observed in binding
experiments, the same general rank order of potency was
observed for transactivation activity. In contrast to the much
higher activity observed in systems expressing any form of
ER, 5-AED exhibits poor AR transactivation. Despite its
clear ER transactivation properties at low nanomolar levels,
5-AED appears to be a modest transactivator of human
estrogen receptor compared to 17β-estradiol (see Table 2).
3.2. Eﬀect of 5-AED in CAR-Induced Pleurisy. All mice,
which had received CAR and were treated with vehicle
alone, developed an acute pleurisy with increased numbers
of inﬁltrating cells (Figure 1). The peak of the cellular
response was between 4 and 6 hours after administration of
CAR. Relative to the negative control mice (vehicle alone),
treatment with 40mg/kg 5-AED suspension signiﬁcantly
reduced the degree of lung-associated inﬂammation as
judged by reduced cellular inﬁltration (at 5 hours) and levels
of pro-inﬂammatory cytokines TNFα and IL-6 (at 4 hours
and 4 and 5 hours, resp.). By 6 hours, the AED-treated
group was nearly identical to the non-AED-treated group for
all parameters shown. Similar kinetic studies were repeated
twice with similar results.
3.3. Eﬀect of 5-AED on Serum Levels of TNFα and Survival
in LPS-Induced Shock. At 1 hour after LPS challenge, serum
levels of TNFα were signiﬁcantly (P<. 05) reduced in
mice treated with 40mg/kg 5-AED suspension compared
to vehicle-treated animals. Lower doses (0.4 and 4.0mg/kg)
were not eﬀective (Figure 2). As reported in our previousAutoimmune Diseases 5
Table 2: Transactivation EC50 values for dihydrotestosterone
(DHT),estradiol(E2)andandrostenediol(5-AED)forAR,ERαand
ERβ.
Ligand Experimental System∗
MDA-kb2
(a) T47D-
kBluc
(b)
ERβ-
HEK293
(c)
DHT 0.06nM ±
0.01 (9) 112nM (1) 409nM ± 92
(6)
E2
851nM ±
172 (6)
0.001nM ±
0.0003 (5)
0.06nM ±
0.02 (9)
5-AED 2969nM ±
790 (7)
2.5nM ±
0.76 (4)
1.7nM ±
0.26 (7)∗∗
∗R e s u l t sa r ee x p r e s s e da sE C 50 values in nM units, representing the
statistical mean ± SEM. The numbers in parenthesis represent the number
of independent experiments performed (n value).
(a)MDA-kb2 cells are stably transfected with a promoter/ reporter construct
sensitive to sex steroid receptor stimulation fused upstream of (MMTV
promoter) a luciferase reporter gene. These cells endogenously express both
AR and glucocorticoid receptors.
(b)T47D-kBluc cells are stably transfected with a synthetic promoter/
reporter construct sensitive to estrogenic stimulation, consisting of 3 copies
of the estrogen response element- (ERE-) fused upstream of a luciferase
reporter gene. These cells express endogenously both ERα and ERβ.
(c)ERβ-HEK293 cells are transiently cotransfected with an ERE/luciferase
promoter/reporter construct and a cDNA expression vector encoding the
full length human ERβ. These cells exhibit virtually undetectable levels of
endogenous sex steroid receptors.
∗∗Although a total of 9 experiments were initially conducted, results from
two experiments were discarded as clear outliers on the basis that their
values fell >1.5 times the interquartile range above the third quartile of the
entire dataset (standard statistical criterion for deﬁning outlier values for a
normally distributed population).
studies [11], mice treated with 40mg/kg 5-AED also expe-
r i e n c e di m p r o v e ds u r v i v a lc o m p a r e dt om i c et r e a t e dw i t h
vehicle alone (100% lethality), but only if 5-AED was given
24 hours before, or one hour after LPS challenge (50%–60%
lethality, resp.). No survival advantage was demonstrated
if 5-AED was given 4, 8, or 24 hours after LPS challenge
(100% lethality; data not shown). Similar survival studies
were repeated three times with similar results.
3.4. Eﬀect of 5-AED in EAE. On day 8 post immunization
to induce EAE, 5 out of 40 mice (12.5%) showed clinical
signs of disease (scores between 1 and 2) and treatment
began in all groups. All of these 5 initially eﬀected animals
had been randomly assigned to 5-AED groups and none
to the vehicle group. First signs of EAE developed in the
vehicle group starting on days 10-11. Subsequently, control
mice developed a classical course of EAE, with a progressive
increase in the clinical score that reached its peak on day
17, followed by recovery (Figure 3(a)). Cumulative disease
score was 25.4±9.3. The incidence of EAE was 100% and no
lethality occurred in the vehicle group. Incidence was 100%
in all groups.
The mice treated with the highest dose of 5-AED
exhibited a milder clinical course of the disease entailing a
signiﬁcantly lower cumulative disease score (14.4 ± 9.1) than
vehicle-treated control mice. (P>. 0 5 ) .At r e n dt o w a r da
milder course of EAE (cumulative disease score 18.1 ± 9.9)
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Figure 2: Eﬀe c to f5 - A E Do ns e r u ml e v e l so fT N F α in a murine
model of LPS-induced shock. CD-1 mice (males, 4 per group) were
treated (s.c. injection) with 5-AED (0.4, 4.0 or 40mg/kg) 24 hours
beforeand1hourafterIPchallengewithLPS(0.5mg).2hoursafter
the LPS challenge, mice were killed and serum levels of TNFα are
measured by ELISA. All values in the ﬁgures are expressed as mean
± one standard deviation. These studies were repeated three times
with similar results. ∗indicates signiﬁcant (P<. 05) diﬀerence when
compared to control values.
was also observed in the mice receiving the 4mg/kg dose
of 5-AED. No lethality occurred in either of these groups.
T h el o w e s td o s eo f5 - A E Dw a sn o te ﬀective in view of the
unexpectedlyhighmortality(6/10)afterday17inthisgroup.
Surviving mice in this group experienced a milder course
of EAE after day 19 to the end of the study (cumulative
disease score 14.5 ± 3.7). The minimally eﬀective dose
appeared in the 4 to 40mg/kg range. In contrast, when
5-AED was given in a soluble formulation (cyclodextran),
associated with short half-life and rapid clearance, there
were no signiﬁcant diﬀerences between 5-AED- and vehicle-
treated groups (Figure 3(b)).
4. Discussion
In conﬁrmation of our earlier work [11], we have shown
thats.c.injectionof5-AEDinsuspensionamelioratesEAEin
female SJL/J mice. The beneﬁcial eﬀect of 5-AED in EAE was
dose dependent and may relate to a neuroprotective activity
mediated by ERβ as well as an anti-inﬂammatory activity,
perhaps mediated by ERα. Evidence for the later comes from
our current observations of reduced or delayed TNFα and
IL-6 concentrations in exudates and cellular inﬁltrates in
carrageenan-induced pleurisy as well as reduced levels of
TNFα and improved survival in LPS-induced shock. This
conﬁrms our own earlier work [11] and work of others [15,
16] and extends our earlier observations to show that 5-AED
treatment only improved 72-hour survival if given 24 hours
before or 1 hour after LPS challenge. TNFα is a key cytokine
implicated in EAE, MS; and many other autoimmune and
acute inﬂammatory diseases [17]. These ﬁndings are largely
in agreement with earlier work of Suzuki and colleagues
[18] and do not discount the potential for involvement of a
physiological response to subcutaneous 5-AED particles as
a component of the pharmacodynamic in mice. Our data6 Autoimmune Diseases
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Figure 3: Eﬀect of 5-AED in suspension (a) and soluble for-
mulation (b) on Experimental Autoimmune Encephalomyelitis.
Disease was induced in female SJL/J mice (n = 10) by subcutaneous
immunization with PLP(139–151). Mice began receiving daily s.c.
injections with (40, 4 or 0.4mg/kg) 5-AED (square, open circle,
open diamond, resp.) or vehicle (triangle) 8–11 days later (onset).
Disease scores were evaluated daily as indicated in Methods. Values
in the ﬁgure are expressed as mean ± one standard deviation (error
bars included for vehicle and 40mg/kg groups). Statistical analysis
of cumulative clinical scores was performed by ANOVA analysis
for unpaired data. A P value <.05 was considered to be statistically
signiﬁcant. For statistical analysis, the mice that succumbed to EAE
wereassigned5onlyforthedayofdeathandthenweredeletedfrom
the experimental group.
presented here and those of others [19], regarding 5-AED
engagement of both ERα and ERβ receptors, suggest that
thesereceptorsmaybemoleculartargetsconsequentialtothe
activity of 5-AED in these models.
The current studies extend our previous report [11]
by showing that the beneﬁt of 5-AED in EAE is dose-
dependent.Atrendforimprovementincumulativescorewas
observed in the 4mg/kg group and statistically signiﬁcant
improvement in cumulative score was observed in the
40mg/kg group. It is unlikely that the unusually high
mortality observed only in the 0.4mg/kg group relates to
ad r u ge ﬀect since 5-AED, even at much higher doses, has
alwaysbeenfoundtobesafeandwelltoleratedinallprevious
studies, including those in SLJ/J female mice with EAE. Our
observation that the 40mg/kg dose of soluble 5-AED was
not eﬀective may relate to the diﬀerential drug exposures
arising from the diﬀerent pharmacokinetics of 5-AED when
administered in a soluble, quick release formulation versus
a suspension form, where the material egresses from the
administration site more slowly. When 5-AED (40mg/kg)
was given to mice as a suspension, a Cmax of up to
∼100ng/mL was attained within one hour and signiﬁcant
levels (∼10ng/mL) of 5-AED persisted for as much as 96
hours. These observations are largely in agreement with
studies of Singh et al. [20]. In contrast, soluble formulations
(cyclodextran)rapidly(withinminutes)achieveahighCmax
(<5,000ng/mL) but with a rapid half-life that results in
complete clearance within 8–12 hours, resulting in no drug
exposure for half the day (Harbor Biosciences, unpublished
observations). However, it remains possible that the failure
of soluble 5-AED in the present studies relates to subtle
diﬀerences in experimental protocols between laboratories
and that soluble formulations of 5-AED may provide beneﬁt
in EAE under diﬀerent experimental conditions.
Published studies demonstrate that beneﬁt in EAE can
be achieved by steroidal engagement of either ERα or ERβ
receptors, the former is attributed to anti-inﬂammatory
action and the later to neuroprotective eﬀects [6, 21]. The
ability of 5-AED to function as a relatively potent ERβ ligand
and only weakly interact with ERα is largely in agreement
with earlier work of Blizzard and colleagues [19]. This
suggests that beneﬁt of 5-AED in EAE may relate to both
properties. The multiple order of the magnitude diﬀerences
in 5-AED transactivation of either human ERα or ERβ
compared to 17β-estradiol indicates that receptor activation
levelssustainedbya5-AEDdepotformulationcouldprovide
therapeuticbeneﬁttopatientswithreducedriskofestrogenic
side eﬀects. This work has not formally shown involvement
of ERα or ERβ in the activity of 5-AED in EAE, nor
have we strictly ruled out any role for androgen receptor.
It remains possible that other receptors are involved, for
example, surface receptors for androgens [22]o re s t r o g e n s
[23]. Although we have shown that 5-AED does not bind to
PPARγ or δ, the α form of the receptor was not tested. This
maybeparticularlyinterestinginlightoftheobservationthat
PPARα knockout mice do not respond to DHEA [24].
Extrapolation of an eﬀective dose of 5-AED in patients
with MS may ﬁnd a basis in studies by Tagawa and colleagues
[25] when considered along with the pregnancy in multiple
sclerosis (PRIMS) study [26]. Tagawa measured serum 5-
AED levels before, during, and after pregnancy. Highest
levels of 5-AED (6.87 ± 1.95nM) occur during pregnancy
and fall post partum, reaching a low of 1.89 ± 0.58nM within
10 months. The PRIMS study reported on relapse rates in
women with MS during the same period. Disease remission
in MS is typically observed during pregnancy and increased
relapse rates are reported afterwards. Thus, changes in 5-
AED in vivo appear to correlate with remitting and relapsing
disease, and if so, maintenance of pregnancy levels of 5-
AED may reduce relapse rates in patients with MS. This
may be achieved with 5-AED sustained release formulations,Autoimmune Diseases 7
providingsafetherapytopatientswithMSandperhapsother
Th1-driven autoimmune diseases.
An injectable 5-AED suspension formulation was deve-
loped as a countermeasure to exposure to ionizing radiation.
This formulation was shown to be safe in Phase I clinical
trials and protected primates against ionizing radiation
[27]. In our clinical studies, we found that injection of
100–200mg sustained serum levels of 5-AED (∼30ng/mL)
comparable to those seen during pregnancy for several weeks
(Stickney et al., in preparation) and suﬃcient to engage
human ERα and ERβ receptors. Taken together with the data
reported here and in our clinical studies, we believe that this
may be a useful formulation of 5-AED, ready to proceed into
phase II testing as treatment for patients with a relapsing
remitting form of MS.
Dehydroepiandrosteone (DHEA), the most abundant
adrenal steroid in the body, is the precursor of sex steroids,
5-AED,andothermetabolitesthathavealsoprovidedbeneﬁt
(including improved histology) in the EAE animal model
[9]. Attempts are being made to address the metabolic
instability and improve the pharmaceutical properties of
these low potency natural compounds with synthetic ana-
logues stabilized to metabolism [28, 29]. An injectable
suspension formulation, however, may represent an alter-
native opportunity, where natural compounds, given in
depot formulation, release superphysiologic concentrations
over a sustained time period. Such an approach may have
additional advantages if the downstream metabolites of
the endogenous hormone also contribute to the overall
therapeutic eﬀect.
The data reported here and in our clinical studies suggest
that treatment of humans with an injectable 5-AED suspen-
sion formulation (100–200mg injection) can sustain serum
levels of 5-AED comparable to those seen during pregnancy
for several weeks, engage ERα and ERβ receptors, and
safely achieve both neuroprotection and anti-inﬂammatory
beneﬁts.Thus,ourinjectable5-AEDsuspensionformulation
may be a useful formulation of 5-AED and is ready to
proceed into phase II testing as treatment for patients with
a relapsing remitting form of MS.
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